MARK2 Protein

MARK2 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MARK2 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>MAP/Microtubule Affinity-Regulating Kinase 2</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[MARK2](/genes/mark2)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q7KZI7](https://www.uniprot.org/uniprot/Q7KZI7)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~80 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, membrane, cell junctions</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>MARK/Par-1 kinase family</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">13 edges</a></td>
</tr>
</table>

MARK2 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MARK2 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>MAP/Microtubule Affinity-Regulating Kinase 2</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[MARK2](/genes/mark2)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q7KZI7](https://www.uniprot.org/uniprot/Q7KZI7)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~80 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, membrane, cell junctions</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>MARK/Par-1 kinase family</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">13 edges</a></td>
</tr>
</table>

MARK2 (MAP/Microtubule Affinity-Regulating Kinase 2), also known as EMK1 or Par-1b, is a serine/threonine kinase that directly phosphorylates [tau](/proteins/tau) and other microtubule-associated proteins at KXGS motifs.[@drewes1997][@timm2003] As a member of the AMPK-related kinase family, MARK2 plays critical roles in establishing neuronal polarity, regulating microtubule dynamics, and modulating axonal transport.[@drewes1997] Dysregulated MARK2 activity has been implicated in [Alzheimer's Disease](/diseases/alzheimers-disease), [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy), and other [tauopathies](/mechanisms/tauopathies).[@timm2003][@chin2010]

Structure

MARK2 has a conserved multidomain architecture shared across the MARK kinase family (MARK1-4):

• N-terminal kinase domain (aa 1–272): Contains the catalytic core with an activation loop that requires phosphorylation at Thr208 by upstream kinases, primarily [LKB1](/entities/lkb1) (STK11).[@drewes1997][@marx2010]
• Ubiquitin-associated (UBA) domain (aa 352–395): Binds ubiquitin chains, potentially regulating kinase activity and protein turnover. Deletion of UBA increases MARK2 activity, suggesting it serves as an intramolecular autoinhibitory module.[@marx2010]
• Spacer region: Flexible linker between UBA and the C-terminal domain, subject to regulatory phosphorylation by atypical [PKC](/genes/pkc) (aPKC) and [GSK-3β](/proteins/gsk3-beta-protein).[@drewes1997]
• Kinase-associated domain 1 (KA1) (aa 486–626): A C-terminal membrane-targeting module that binds acidic phospholipids, directing MARK2 to the plasma membrane for polarity signaling.[@marx2010]

Normal Function

Microtubule Regulation

MARK2 phosphorylates the KXGS motifs within the microtubule-binding repeats of [tau](/proteins/tau) (notably Ser262 and Ser356), [MAP2](/proteins/map2-protein), and MAP4.[@drewes1997][@timm2003] This phosphorylation reduces MAP-microtubule binding affinity, increasing microtubule dynamic instability. This detachment mechanism is essential for microtubule remodeling during neuronal migration, axon branching, and synaptic plasticity.[@drewes1997]

Neuronal Polarity

MARK2 is essential for establishing axon-dendrite polarity in developing [neurons](/entities/neurons). In the LKB1-MARK polarity pathway, [LKB1](/entities/lkb1) activates MARK2, which then phosphorylates tau to locally destabilize microtubules in future dendritic processes while allowing the single axon to elongate.[@chen2006] Overexpression of MARK2 produces multiple axons, while kinase-dead MARK2 prevents axon specification.[@chen2006] The asymmetric distribution of MARK2 activity, regulated by Par3-Par6-aPKC signaling, creates the polarity break that defines neuronal morphology.[@chen2006]

Axonal Transport

By regulating the attachment of MAPs to microtubules, MARK2 indirectly controls the efficiency of kinesin- and dynein-mediated axonal transport.[@drewes1997] Excessive MARK2 activity strips MAPs from microtubule tracks, impairing cargo motility — a mechanism directly relevant to axonal transport failure in neurodegeneration.

Role in Neurodegeneration

Alzheimer's Disease

Phosphorylation of tau at Ser262 by MARK kinases is among the earliest detectable tau modifications in AD brain and is thought to be a priming event that precedes phosphorylation at downstream sites by [GSK-3β](/proteins/gsk3-beta-protein) and [CDK5](/proteins/cdk5-protein).[@timm2003][@chin2010] The Ser262 site lies within the first microtubule-binding repeat and its phosphorylation alone reduces tau-microtubule binding by approximately 80%.[@timm2003] In Drosophila tauopathy models, mutating the MARK-targeted KXGS sites to non-phosphorylatable alanines completely blocks tau toxicity, demonstrating that MARK-mediated phosphorylation is necessary (not merely correlative) for tau-induced neurodegeneration.[@nishimura2004] MARK2 expression is upregulated in AD [hippocampus](/brain-regions/hippocampus), and MARK2 colocalizes with pre-tangle tau in early Braak stage neurons.[@chin2010]

Progressive Supranuclear Palsy and Other Tauopathies

In [PSP](/diseases/progressive-supranuclear-palsy) and [corticobasal degeneration](/diseases/corticobasal-degeneration), MARK-phosphorylated tau epitopes (detected by the 12E8 antibody against pSer262/pSer356) are prominent in the characteristic globose neurofibrillary tangles and tufted [astrocytes](/entities/astrocytes).[@chin2010] The predominance of [4R-tau](/proteins/4r-tau) isoforms in these disorders may render them particularly susceptible to MARK-mediated destabilization, as 4R-tau has an additional KXGS-containing repeat domain.[@sergeant2008]

Parkinson's Disease

MARK2 has been reported to phosphorylate [alpha-synuclein](/proteins/alpha-synuclein) at Ser129, the pathological phosphorylation site enriched in Lewy bodies, though this remains less established than its tau kinase activity.[@lizcano2004] MARK2 also regulates mitochondrial dynamics through phosphorylation of mitochondrial fission/fusion machinery components.

Therapeutic Implications

MARK kinases represent an attractive but challenging therapeutic target:

• Selective MARK inhibitors: Compounds targeting the MARK kinase domain must achieve selectivity over the >20 other AMPK-related kinases. Several tool compounds have been described but none have reached clinical development.[@marx2010]
• LKB1-MARK axis modulation: Upstream inhibition of the LKB1-MARK signaling axis could reduce pathological tau phosphorylation, but LKB1 is also a tumor suppressor, creating potential oncogenic liability.[@marx2010]
• Combination approach: Since MARK phosphorylation at Ser262 primes tau for subsequent phosphorylation by [GSK-3β](/entities/gsk3-beta) and [CDK5](/proteins/cdk5), co-targeting MARK and these downstream kinases may provide synergistic reduction of tau hyperphosphorylation.[@timm2003][@chin2010]
• Biomarker potential: Antibodies detecting MARK-specific tau phosphoepitopes (12E8 antibody against pSer262/pSer356) could serve as early biomarkers of tau pathology initiation.[@chin2010]

See Also

• [Tau Protein](/proteins/tau)
• [Tau Hyperphosphorylation](/mechanisms/tau-hyperphosphorylation)
• [GSK-3β](/proteins/gsk3-beta-protein)
• [CDK5](/proteins/cdk5-protein)
• [LKB1](/entities/lkb1)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)

External Links

• [UniProt: MARK2 (Q7KZI7)](https://www.uniprot.org/uniprot/Q7KZI7)
• [NCBI Protein: MARK2](https://www.ncbi.nlm.nih.gov/protein/NP_001027.3)
• [GeneCards: MARK2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MARK2)

References